Psychiatric Times

Premier online and print content, written by and for #mentalhealth care physicians and professionals. Questions? Email: [email protected].

[Psychiatric Times @PsychTimes]

🚨 The FDA has approved olanzapine (Weltruza) extended-release injectable suspension, a once-monthly subcutaneous long-acting injectable, for adults with schizophrenia. https://t.co/msiSo8994U

[Psychiatric Times @PsychTimes]

Check out the latest episode of "Psychopharm Today"! This month, host Jessica Gannon, MD, interviews Andrew A. Nierenberg, MD, about how a learning health network can transform bipolar disorder care.

Watch it here: https://t.co/QedaL5fily

Listen here: https://t.co/xqkufG0lo1

[Psychiatric Times @PsychTimes]

The October issue of Psychiatric Times is now live! This month, we're rethinking treatment resistance and measurement-based care.

Download the issue now and follow along as articles are shared throughout the month. https://t.co/ghCkRDRjhD

[Psychiatric Times @PsychTimes]

The FDA has cleared Motivista, a prescription digital therapeutic indicated for the negative symptoms of schizophrenia, as an adjunct to outpatient care. This is the first authorized treatment for negative symptoms of schizophrenia in the United States. https://t.co/JqKYf8JfD2

[Psychiatric Times @PsychTimes]

A recent study found that vortioxetine was consistently associated with improvements in depressive symptoms, though improvements in cognitive symptoms were inconsistent, with neutral-to-positive, predominantly domain-specific effects. https://t.co/Q0xIF1BuM4

[Psychiatric Times @PsychTimes]

🌴 Join leading psychiatry experts in Aventura, FL, Dec. 4–5 for the 2026 Southern Florida Psychiatry Conference!

Gain practical insights and strategies to enhance patient care.

🔗Register now: https://t.co/E3Z8lC77V2

#SoFloPsych #Psychiatry #MentalHealth #CME

[Psychiatric Times @PsychTimes]

Our October theme: PTSD.

If you are interested in being featured in a future Special Report/print issue, submit to our content series! https://t.co/n2wLYmqmrF

[Psychiatric Times @PsychTimes]

Q3 2026 has come to an end. What were the highlights from the psychopharmacology pipeline and FDA this quarter? Find out here: https://t.co/4dGOy9Vavh

[Psychiatric Times @PsychTimes]

🍂💊 Check out all the psychopharmacology pipeline & FDA updates from September: https://t.co/RE5BP35yYu

[Psychiatric Times @PsychTimes]

A new cross-sectional study found that 49.0% of US adults who used both alcohol and cannabis in the past month reported using them simultaneously, despite potential compounded risks, including impaired judgment, injury, and intoxication effects. https://t.co/2UNvQZSh4q

[Psychiatric Times @PsychTimes]

Pharmacologic interventions are a critical component of comprehensive suicide prevention. Among currently available interventions, lithium and clozapine have the strongest evidence for reducing suicidal behavior over time: https://t.co/rLF3MUT4J0

[Nicolas Badre @BadreNicolas]

Are we adults at 18?

Courts are repeatedly told by colleagues of mine that people under 25 are impulsive and cannot make decisions for themselves.

The claim is dressed up as neuroscience. What is usually missing is an examination of the actual person. A few years ago I wrote about the same problem with PTSD. This is the next one.

My latest in @PsychTimes:
https://t.co/KKFd51aqZA

[Psychiatric Times @PsychTimes]

Whether you are a psychiatrist, a therapist, or someone who's ever Googled "is my anxiety actually my heart," this conversation is the curbside consult you wish you'd had sooner: https://t.co/2RIN6fkMfC

[Psychiatric Times @PsychTimes]

Survey data show that nearly 34% of women and 17% of men have experienced contact sexual violence, physical violence, or stalking by an intimate partner during their lifetime. https://t.co/unZwLhWeiG

[Psychiatric Times @PsychTimes]

🚨 The FDA has granted Breakthrough Device Designation to NET Recovery for its NET Device as an aid in reducing psychostimulant use in adults 18 and older diagnosed with stimulant use disorder. https://t.co/YbwBCFNoYq

[Psychiatric Times @PsychTimes]

Explore evolving perspectives on the diagnosis, management and treatment considerations in major depressive disorder and bipolar I disorder. Read more: https://t.co/mTTIBK2U21 #Sponsored

[Psychiatric Times @PsychTimes]

🎙️ The Psych Consult: Second Opinion is here!

Claire Brandon, MD, and cardiologist Lara Oboler, MD, explore how SVT and POTS can mimic panic attacks, the clues that can help distinguish them, and why cardiac and psychiatric care can go hand in hand.

🔗 https://t.co/WgcUDzvRzT

[Psychiatric Times @PsychTimes]

How can body-based technologies help target 2 of the most challenging symptoms to treat in psychiatry, dissociation and anhedonia?

@schoeller_felix, the founder of ReWire Neurotechnologies, shares more in our September issue: https://t.co/ioFJzob1Ss

[Psychiatric Times @PsychTimes]

Denial of suicidal intent in adolescents after firearm injury can coexist with high-risk behaviors, necessitating assessment beyond self-report, particularly when affect appears constricted or emotionally numb. https://t.co/S3WlYtR2eN

[Psychiatric Times @PsychTimes]

Last chance to register for Jersey City Psychiatry 2026! 🧠

Join fellow mental health professionals October 2–3 in Jersey City, NJ, for 2 days of education, connection & conversations on the latest in psychiatric care.

Register: https://t.co/fok1Qmp3EY #JCPsych2026